摘要
目的 分析二甲双胍恩格列净片联合德谷胰岛素利拉鲁肽治疗2型糖尿病的药效价值。方法 选取2023年1月—2024年1月本院收治的2型糖尿病患者60例为研究观察对象,依据随机数字法分为对照组(予以德谷胰岛素利拉鲁肽治疗)、观察组(予以德谷胰岛素利拉鲁肽+二甲双胍恩格列净片联合治疗),分析两组糖脂代谢情况、安全性、患者治疗接受情况。结果 治疗后,对两组患者进行空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)及总胆固醇(TC)的测定,结果显示观察组的上述指标均低于对照组,差异有统计学意义(P<0.05)。进一步分析治疗后胰岛素分泌指数(HOMA-β),观察组的指数显著高于对照组,差异有统计学意义(P<0.05)。治疗后两组总不良反应发生率的比较,差异无统计学意义(P>0.05)。治疗后分析两组患者依从性、接受程度、便利性、经济性情况,观察组较对照组高(P<0.05)。结论 治疗2型糖尿病在德谷胰岛素利拉鲁肽治疗基础上增加二甲双胍恩格列净片可以显著改善患者糖代谢状态,治疗不会明显增加不良反应,且可以满足患者治疗便利性、经济性等需求。
Objective To analyze the pharmacological value of metformin and empagliflozin tablets combined with deglude insulin and liraglutide in the treatment of type 2 diabetes.Methods From January 2023 to January 2024,60 patients with type 2 diabetes were treated in our hospital as the research observation objects.According to the random envelope method,the control group(degludec and liraglutide treatment)and the observation group(degludec insulin and liraglutide metformin and Empagliflozin tablets combined treatment)were divided.The two groups were analyzed for glucose and lipid metabolism,safety,and patient treatment acceptance.Results After treatment,the fasting plasma glucose(FPG),2-hour postprandial glucose(2 hPG),glycosylated hemoglobin(HbA1c),and total cholesterol were analyzed in the two groups,and the observation group was lower than the control group(P<0.05).After treatment,the insulin secretion(HOMA-β)was analyzed in the two groups,and the observation group was higher than the control group(P<0.05).treatment,the total incidence of adverse reactions was analyzed,and there was no statistical difference between the two groups(P>0.05).After treatment,compliance,acceptance,convenience,and economy of the two groups of patients were analyzed,and the observation group was higher than the control group(P<0.5).Conclusion In the treatment of type 2 diabetes,adding metformin and empagliflozin tablets on the basis of degludec insulin andiraglutide treatment can significantly improve the patient's glucose metabolism status,and the treatment will not significantly increase adverse reactions,and can meet the patient's treatment convenience economy and other needs.
作者
孙林
SUN Lin(The Second People's Hospital of Pingliang,Pingliang,Gansu 744000)
出处
《智慧健康》
2025年第13期76-78,83,共4页
Smart Healthcare
作者简介
孙林(1986-),男,汉族,甘肃平凉人,本科,主治医师,研究方向:代谢综合征、糖尿病及其慢性并发症、高尿酸血症、肥胖、骨质疏松的诊治。
